Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kristian Holm is active.

Publication


Featured researches published by Kristian Holm.


Nature Genetics | 2011

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.

Espen Melum; Andre Franke; Christoph Schramm; Tobias J. Weismüller; Daniel Gotthardt; Felix Offner; Brian D. Juran; Jon K. Laerdahl; Verena Labi; Einar Björnsson; Rinse K. Weersma; Liesbet Henckaerts; Andreas Teufel; Christian Rust; Eva Ellinghaus; Tobias Balschun; Kirsten Muri Boberg; David Ellinghaus; Annika Bergquist; Peter Sauer; Euijung Ryu; Johannes R. Hov; Jochen Wedemeyer; Björn Lindkvist; Michael Wittig; Robert J. Porte; Kristian Holm; Christian Gieger; H-Erich Wichmann; Pieter Stokkers

Primary sclerosing cholangitis (PSC) is a chronic bile duct disease affecting 2.4–7.5% of individuals with inflammatory bowel disease. We performed a genome-wide association analysis of 2,466,182 SNPs in 715 individuals with PSC and 2,962 controls, followed by replication in 1,025 PSC cases and 2,174 controls. We detected non-HLA associations at rs3197999 in MST1 and rs6720394 near BCL2L11 (combined P = 1.1 × 10−16 and P = 4.1 × 10−8, respectively).


Journal of Hepatology | 2012

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci

Trine Folseraas; Espen Melum; Philipp Rausch; Brian D. Juran; Eva Ellinghaus; Alexey Shiryaev; Jon K. Laerdahl; David Ellinghaus; Christoph Schramm; Tobias J. Weismüller; Daniel Gotthardt; Johannes R. Hov; O. P. F. Clausen; Rinse K. Weersma; Marcel Janse; Kirsten Muri Boberg; Einar Björnsson; Hanns-Ulrich Marschall; Isabelle Cleynen; Philip Rosenstiel; Kristian Holm; Andreas Teufel; Christian Rust; Christian Gieger; H-Erich Wichmann; Annika Bergquist; Euijung Ryu; Cyriel Y. Ponsioen; Heiko Runz; Martina Sterneck

BACKGROUND & AIMS A limited number of genetic risk factors have been reported in primary sclerosing cholangitis (PSC). To discover further genetic susceptibility factors for PSC, we followed up on a second tier of single nucleotide polymorphisms (SNPs) from a genome-wide association study (GWAS). METHODS We analyzed 45 SNPs in 1221 PSC cases and 3508 controls. The association results from the replication analysis and the original GWAS (715 PSC cases and 2962 controls) were combined in a meta-analysis comprising 1936 PSC cases and 6470 controls. We performed an analysis of bile microbial community composition in 39 PSC patients by 16S rRNA sequencing. RESULTS Seventeen SNPs representing 12 distinct genetic loci achieved nominal significance (p(replication) <0.05) in the replication. The most robust novel association was detected at chromosome 1p36 (rs3748816; p(combined)=2.1 × 10(-8)) where the MMEL1 and TNFRSF14 genes represent potential disease genes. Eight additional novel loci showed suggestive evidence of association (p(repl) <0.05). FUT2 at chromosome 19q13 (rs602662; p(comb)=1.9 × 10(-6), rs281377; p(comb)=2.1 × 10(-6) and rs601338; p(comb)=2.7 × 10(-6)) is notable due to its implication in altered susceptibility to infectious agents. We found that FUT2 secretor status and genotype defined by rs601338 significantly influence biliary microbial community composition in PSC patients. CONCLUSIONS We identify multiple new PSC risk loci by extended analysis of a PSC GWAS. FUT2 genotype needs to be taken into account when assessing the influence of microbiota on biliary pathology in PSC.


Nature Genetics | 2016

Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota

Jun Wang; Louise B. Thingholm; Jurgita Skiecevičienė; Philipp Rausch; Martin Kummen; Johannes R. Hov; Frauke Degenhardt; Femke-Anouska Heinsen; Malte C. Rühlemann; Silke Szymczak; Kristian Holm; Tonu Esko; Jun Sun; Mihaela Pricop-Jeckstadt; Samer Al-Dury; Pavol Bohov; Jörn Bethune; Felix Sommer; David Ellinghaus; Rolf K. Berge; Matthias Hübenthal; Manja Koch; Karin Schwarz; Gerald Rimbach; Patricia Hübbe; Wei-Hung Pan; Raheleh Sheibani-Tezerji; Robert Häsler; Philipp Rosenstiel; Mauro D'Amato

Human gut microbiota is an important determinant for health and disease, and recent studies emphasize the numerous factors shaping its diversity. Here we performed a genome-wide association study (GWAS) of the gut microbiota using two cohorts from northern Germany totaling 1,812 individuals. Comprehensively controlling for diet and non-genetic parameters, we identify genome-wide significant associations for overall microbial variation and individual taxa at multiple genetic loci, including the VDR gene (encoding vitamin D receptor). We observe significant shifts in the microbiota of Vdr−/− mice relative to control mice and correlations between the microbiota and serum measurements of selected bile and fatty acids in humans, including known ligands and downstream metabolites of VDR. Genome-wide significant (P < 5 × 10−8) associations at multiple additional loci identify other important points of host–microbe intersection, notably several disease susceptibility genes and sterol metabolism pathway components. Non-genetic and genetic factors each account for approximately 10% of the variation in gut microbiota, whereby individual effects are relatively small.


Hepatology | 2013

Genome-Wide Association Analysis in Primary Sclerosing Cholangitis and Ulcerative Colitis Identifies Risk Loci at GPR35 and TCF4

David Ellinghaus; Trine Folseraas; Kristian Holm; Eva Ellinghaus; Espen Melum; Tobias Balschun; Jon K. Laerdahl; Alexey Shiryaev; Daniel Gotthardt; Tobias J. Weismüller; Christoph Schramm; Michael Wittig; Annika Bergquist; Einar Björnsson; Hanns-Ulrich Marschall; Morten H. Vatn; Andreas Teufel; Christian Rust; Christian Gieger; H-Erich Wichmann; Heiko Runz; Martina Sterneck; Christian Rupp; Felix Braun; Rinse K. Weersma; Cisca Wijmenga; Cyriel Y. Ponsioen; Christopher G. Mathew; Paul Rutgeerts; Severine Vermeire

Approximately 60%‐80% of patients with primary sclerosing cholangitis (PSC) have concurrent ulcerative colitis (UC). Previous genome‐wide association studies (GWAS) in PSC have detected a number of susceptibility loci that also show associations in UC and other immune‐mediated diseases. We aimed to systematically compare genetic associations in PSC with genotype data in UC patients with the aim of detecting new susceptibility loci for PSC. We performed combined analyses of GWAS for PSC and UC comprising 392 PSC cases, 987 UC cases, and 2,977 controls and followed up top association signals in an additional 1,012 PSC cases, 4,444 UC cases, and 11,659 controls. We discovered novel genome‐wide significant associations with PSC at 2q37 [rs3749171 at G‐protein‐coupled receptor 35 (GPR35); P = 3.0 × 10−9 in the overall study population, combined odds ratio [OR] and 95% confidence interval [CI] of 1.39 (1.24‐1.55)] and at 18q21 [rs1452787 at transcription factor 4 (TCF4); P = 2.61 × 10−8, OR (95% CI) = 0.75 (0.68‐0.83)]. In addition, several suggestive PSC associations were detected. The GPR35 rs3749171 is a missense single nucleotide polymorphism resulting in a shift from threonine to methionine. Structural modeling showed that rs3749171 is located in the third transmembrane helix of GPR35 and could possibly alter efficiency of signaling through the GPR35 receptor. Conclusion: By refining the analysis of a PSC GWAS by parallel assessments in a UC GWAS, we were able to detect two novel risk loci at genome‐wide significance levels. GPR35 shows associations in both UC and PSC, whereas TCF4 represents a PSC risk locus not associated with UC. Both loci may represent previously unexplored aspects of PSC pathogenesis. (HEPATOLOGY 2013;58:1074–1083)


BMC Bioinformatics | 2010

SNPexp - A web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels

Kristian Holm; Espen Melum; Andre Franke; Tom H. Karlsen

BackgroundExpression levels for 47294 transcripts in lymphoblastoid cell lines from all 270 HapMap phase II individuals, and genotypes (both HapMap phase II and III) of 3.96 million single nucleotide polymorphisms (SNPs) in the same individuals are publicly available. We aimed to generate a user-friendly web based tool for visualization of the correlation between SNP genotypes within a specified genomic region and a gene of interest, which is also well-known as an expression quantitative trait locus (eQTL) analysis.ResultsSNPexp is implemented as a server-side script, and publicly available on this website: http://tinyurl.com/snpexp. Correlation between genotype and transcript expression levels are calculated by performing linear regression and the Wald test as implemented in PLINK and visualized using the UCSC Genome Browser. Validation of SNPexp using previously published eQTLs yielded comparable results.ConclusionsSNPexp provides a convenient and platform-independent way to calculate and visualize the correlation between HapMap genotypes within a specified genetic region anywhere in the genome and gene expression levels. This allows for investigation of both cis and trans effects. The web interface and utilization of publicly available and widely used software resources makes it an attractive supplement to more advanced bioinformatic tools. For the advanced user the program can be used on a local computer on custom datasets.


Gut | 2017

The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.

Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte Lie Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H. Karlsen; Johannes R. Hov

Objective Gut microbiota could influence gut, as well as hepatic and biliary immune responses. We therefore thoroughly characterised the gut microbiota in primary sclerosing cholangitis (PSC) compared with healthy controls (HC) and patients with ulcerative colitis without liver disease. Design We prospectively collected 543 stool samples. After a stringent exclusion process, bacterial DNA was submitted for 16S rRNA gene sequencing. PSC and HC were randomised to an exploration panel or a validation panel, and only significant results (p<0.05, QFDR<0.20) in both panels were reported, followed by a combined comparison of all samples against UC. Results Patients with PSC (N=85) had markedly reduced bacterial diversity compared with HC (N=263, p<0.0001), and a different global microbial composition compared with both HC (p<0.001) and UC (N=36, p<0.01). The microbiota of patients with PSC with and without IBD was similar. Twelve genera separated PSC and HC, out of which 11 were reduced in PSC. However, the Veillonella genus showed a marked increase in PSC compared with both HC (p<0.0001) and UC (p<0.02). Using receiver operating characteristic analysis, Veillonella abundance yielded an area under the curve (AUC) of 0.64 to discriminate PSC from HC, while a combination of PSC-associated genera yielded an AUC of 0.78. Conclusions Patients with PSC exhibited a gut microbial signature distinct from both HC and UC without liver disease, but similar in PSC with and without IBD. The Veillonella genus, which is also associated with other chronic inflammatory and fibrotic conditions, was enriched in PSC.


AIDS | 2015

Gut microbiota diversity predicts immune status in HIV-1 infection.

Piotr Nowak; Marius Trøseid; Avershina E; Babilonia Barqasho; Ujjwal Neogi; Kristian Holm; Hov; Kajsa Noyan; Jan Vesterbacka; Jenny Svärd; Knut Rudi; Anders Sönnerborg

Objective:HIV-1 infection is characterized by altered intestinal barrier, gut microbiota dysbiosis, and systemic inflammation. We hypothesized that changes of the gut microbiota predict immune dysfunction and HIV-1 progression, and that antiretroviral therapy (ART) partially restores the microbiota composition. Design:An observational study including 28 viremic patients, three elite controllers, and nine uninfected controls. Blood and stool samples were collected at baseline and for 19 individuals at follow-up (median 10 months) during ART. Methods:Microbiota composition was determined by 16S rRNA sequencing (Illumina MiSeq). Soluble markers of microbial translocation and monocyte activation were analyzed by Limulus Amebocyte Lysate assay or ELISA. Results:Several alpha-diversity measures, including number of observed bacterial species and Shannon index, were significantly lower in viremic patients compared to controls. The alpha diversity correlated with CD4+ T-cell counts and inversely with markers of microbial translocation and monocyte activation. In multivariate linear regression, for every age and sex-adjusted increase in the number of bacterial species, the CD4+ T-cell count increased with 0.88 (95% confidence interval 0.35–1.41) cells/&mgr;l (P = 0.002). After introduction of ART, microbiota alterations persisted with further reduction in alpha diversity. The microbiota composition at the genus level was profoundly altered in viremic patients, both at baseline and after ART, with Prevotella reduced during ART (P < 0.007). Conclusions:Gut microbiota alterations are closely associated with immune dysfunction in HIV-1 patients, and these changes persist during short-term ART. Our data implicate that re-shaping the microbiota may be an adjuvant therapy in patients commencing successful ART.


Scandinavian Journal of Gastroenterology | 2009

Small intestinal neuroendocrine tumors: Prognostic factors and survival

Deidi S. Bergestuen; Lars Aabakken; Kristian Holm; Morten H. Vatn; Espen Thiis-Evensen

Objective. Small intestinal neuroendocrine tumors (SI-NETs) make up 38% of gastroenteropancreatic neuroendocrine tumors. We report our experience with SI-NETs at the National Center for Neuroendocrine Tumors in Norway, focusing on prognostic factors and survival. Material and methods. The medical records of 258 patients with SI-NETs diagnosed between 1983 and 2007 were retrospectively reviewed. Demographic, clinical and tumor characteristics were registered in a database. Results. Median age at diagnosis was 62 years (range 28–84); 53% of patients were men. Median survival was 9.3 years [95% confidence interval (CI) 7.6;10.8]. Survival did not improve for patients diagnosed between 1998 and 2007 compared with those diagnosed between 1990 and 1997 (p=0.44), median survival 8.1 [7.1;9.1] versus 6.8 [4.0;9.5] years. Overall 5-year survival was 72%, while expected 5-year survival in the general population was 92%. The corresponding relative 5-year survival for the patient group was 78%. Distant metastases, urinary 5-hydroxyindoleacetic acid ratio ≥3.7 times the upper limit of normal, chromogranin A ratio ≥6.2 times the upper limit of normal, age ≥64, male gender, carcinoid heart disease, and Ki-67 ≥5% were associated with decreased survival. Using multivariate analysis, only distant metastases (hazard ratio (HR) 1.98 [1.04;3.76], p=0.04), chromogranin A ratio ≥6.2 (HR 1.90 [1.12;3.20], p=0.02), and age ≥64 (3.12 [1.93;5.04], p<0.001) remained independent predictors. Conclusions. Survival did not improve over the study period. Overall and relative 5-year survival compared favorably with that in population-based studies. Distant metastases, elevated chromogranin A levels, and advanced age were the only independent predictors of poor survival.


Journal of Acquired Immune Deficiency Syndromes | 2015

Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART

Birgitte Stiksrud; Piotr Nowak; Felix Chinweije Nwosu; Dag Kvale; Anders Thalme; Anders Sönnerborg; Per Magne Ueland; Kristian Holm; Birkeland Se; Dahm Ae; Per Morten Sandset; Knut Rudi; Hov; Anne Ma Dyrhol-Riise; Marius Trøseid

Background:Microbial translocation and chronic inflammation may contribute to non-AIDS morbidity in patients with HIV. This study assessed the impact of probiotic intervention on microbial translocation and inflammation in patients on antiretroviral therapy with viral suppression and subnormal CD4 count. Methods:Thirty-two patients receiving antiretroviral therapy (CD4 <500 cells/&mgr;L) were randomized in a double-blind fashion to multistrain daily probiotics (n = 15), placebo (n = 9), or controls (n = 8) for 8 weeks. Soluble inflammation markers, D-dimer, lipopolysaccharide (LPS), sCD14, T-cell activation, tryptophan metabolites, and gut microbiota composition were analyzed at baseline and end of study. Nonparametric statistics were applied. Results:Twenty-four participants completed the study and were included in as-treated analyses. In patients receiving probiotics, there was a significant reduction in D-dimer levels (median change 33%, P = 0.03) and a tendency to reduced levels of C-reactive protein (CRP) (P = 0.05) and interleukin (IL)-6 (P = 0.06). The changes in CRP and IL-6 were highly correlated (r = 0.95, P < 0.01), whereas changes in D-dimer did not correlate with changes in CRP or IL-6. Increases in Bifidobacteria (P = 0.04) and Lactobacilli (P = 0.06) were observed in the probiotic group, whereas the relative abundance of Bacteroides decreased (P ⩽ 0.01). No significant changes were seen in markers of microbial translocation or T-cell activation. However, the expansion of Bifidobacteria correlated negatively with differences in LPS (r = −0.77, P = 0.01), whereas the reduction in Bacteroides correlated positively with changes in LPS during the study period (r = 0.72, P = 0.02). Conclusions:Probiotic intervention seemed to reduce markers of coagulation and inflammation without overt changes in microbial translocation. These findings warrant further studies in larger cohorts with long-term follow-up.


Hepatology | 2016

High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.

Evaggelia Liaskou; Eva Kristine Klemsdal Henriksen; Kristian Holm; Fatemeh Kaveh; David Hamm; Janine Fear; Marte K. Viken; Johannes R. Hov; Espen Melum; Harlan Robins; Johanna Olweus; Tom H. Karlsen; Gideon M. Hirschfield

Hepatic T‐cell infiltrates and a strong genetic human leukocyte antigen association represent characteristic features of various immune‐mediated liver diseases. Conceptually the presence of disease‐associated antigens is predicted to be reflected in T‐cell receptor (TCR) repertoires. Here, we aimed to determine if disease‐associated TCRs could be identified in the nonviral chronic liver diseases primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and alcoholic liver disease (ALD). We performed high‐throughput sequencing of the TCRβ chain complementarity‐determining region 3 of liver‐infiltrating T cells from PSC (n = 20), PBC (n = 10), and ALD (n = 10) patients, alongside genomic human leukocyte antigen typing. The frequency of TCRβ nucleotide sequences was significantly higher in PSC samples (2.53 ± 0.80, mean ± standard error of the mean) compared to PBC samples (1.13 ± 0.17, P < 0.0001) and ALD samples (0.62 ± 0.10, P < 0.0001). An average clonotype overlap of 0.85% was detected among PSC samples, significantly higher compared to the average overlap of 0.77% seen within the PBC (P = 0.024) and ALD groups (0.40%, P < 0.0001). From eight to 42 clonotypes were uniquely detected in each of the three disease groups (≥30% of the respective patient samples). Multiple, unique sequences using different variable family genes encoded the same amino acid clonotypes, providing additional support for antigen‐driven selection. In PSC and PBC, disease‐associated clonotypes were detected among patients with human leukocyte antigen susceptibility alleles. Conclusion: We demonstrate liver‐infiltrating disease–associated clonotypes in all three diseases evaluated, and evidence for antigen‐driven clonal expansions. Our findings indicate that differential TCR signatures, as determined by high‐throughput sequencing, may represent an imprint of distinctive antigenic repertoires present in the different chronic liver diseases; this thereby opens up the prospect of studying disease‐relevant T cells in order to better understand and treat liver disease. (Hepatology 2016;63:1608‐1619)

Collaboration


Dive into the Kristian Holm's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom H. Karlsen

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar

Espen Melum

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar

Annika Bergquist

Karolinska University Hospital

View shared research outputs
Top Co-Authors

Avatar

Daniel Gotthardt

University Hospital Heidelberg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Kummen

Oslo University Hospital

View shared research outputs
Top Co-Authors

Avatar

Rinse K. Weersma

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge